- >
- News & Events
- >
- Press Releases
Press Releases
Page 2 of 29
Onxeo’s Combined General Meeting on June 10, 2021 in camera: availability of preparatory documents and live webcast login information
Paris (France), May 21, 2021 – 5:45 p.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo”, […]
05/21/2021
Publication of the 2020 Annual Financial Report
Paris (France), April 23, 2021 – 7.00 pm CEST – Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: […]
Tags: Financials & Corporate
04/23/2021
Onxeo Reports Full-Year 2020 Financial Results and Provides Business Update
Several major clinical milestones achieved in 2020 by AsiDNA™, including promising initial results in combination with chemotherapy and the launch […]
04/21/2021
Onxeo announces the success of its Rights Issue with €9.7 million raised
This transaction will accelerate the development of the Company and its portfolio and extend its financial horizon to the end […]
04/12/2021
Onxeo to Present New Preclinical Data at AACR 2021
Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug […]
04/08/2021
Onxeo will publish its annual results on April 21, 2021
The Annual General Meeting will be held on June 10, 2021 Paris (France), March 24, 2021 – 6 pm CET […]
Tags: Financials & Corporate
03/24/2021
Onxeo Launches a Rights Issue to accelerate its R&D programs
This transaction will secure the financing of the strategy and the resources necessary to achieve key clinical milestones until at […]
03/10/2021
Onxeo Enters Clinical Research Agreement with Institut Curie to Conduct a phase 1b/2 Clinical Trial of AsiDNA™ in combination with radiotherapy for Treatment of High-Grade Glioma Relapse in Children
This study is supported by a grant from the European Fight Kids Cancer program[1] Paris (France), February 4, 2021 […]
02/04/2021
Onxeo publishes Letter to Shareholders and provides update on its developments
Paris (France), February 2, 2021 – 9 pm CET – Onxeo S.A. (Euronext Growth: ALONX; Nasdaq First North: ONXEO), a […]
02/02/2021
Page 2 of 29